What service do you need? Contact Request

NCT04953780

Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Diagnosed AML

← Hub

Registry fields

Overall status: ACTIVE_NOT_RECRUITING
Conditions: Acute Myeloid Leukemia
Study type: INTERVENTIONAL
Phase: PHASE1
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: Calaspargase pegol-mknl
Lead sponsor: West Virginia University (OTHER)

Cached at: 2026-09-03 05:09:16

View on ClinicalTrials.gov

Brief summary

Characterizing the regimen limiting toxicity (RLT) of chemotherapeutic drug Calaspargase Pegol-mknl as remission induction and consolidation chemotherapy in patients with newly diagnosed Acute Myeloid Leukemia (AML) and Identifying the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Calaspargase Pegol-mknl.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report